Embed Size (px)
Citation preview
| 1 |www.bwge.be
A DIGITAL EXPERIENCE
XXXIIIrdE D I T I O N03 > 05.03.21
D I G I TA L
33RD
EDITIONScientific sessions
SatelliteSymposia
Grants & Prizes
Invited lectures
Video conference
| 2 |
WE
DN
ES
DA
Y 0
3/
03
FR
ID
AY
0
5/
03
OverView BGWE 2021
FR
ID
AY
0
5/
03
TH
UR
SD
AY
0
4/
03
PAVILION 1 PAVILION 2
Room ANTWERP Room BRUSSELS Room GENT Room LIEGE
■ 14.00-15.50 IBD - BIRD
■ 16.05-18.30 IBD - BIRD
■ 08.30-10.10 PGC
■ 10.30-12.10 PGC
■ 13.15-14.55 PGC
■ 15.15-16.55 PGC
■ 17.15-19.20 UltraSound Course
■ 08.30-10.30 BASL - BLIC
■ 9.30-10.00 Brohée Lecture
■ 10.00-10.30 Symposium EISAI/MSD
■ 10.45-12.40 BASL - BLIC
■ 14.00-14.30 Symposium ALNYLAM
■ 14.30-15.45 BASL - BLIC
■ 08.30-10.30 Case Reports
■ 10.45-12.40 Case Reports
■ 13.00-14.00 BeSPGHAN GA
■ 14.00-15.10 BeSPGHAN
■ 15.10-15.40 Symposium ABBVIE
■ 15.40-16.50 BeSPGHAN
■ 08.30-10.25 GIREM
■ 10.45-12.35 GIREM
■ 13.30-15.00 GIREM
■ 13.30-14.00 Symposium MEDTRONIC
■ 14.00-15.36 BSGIE
■ 15.36-17.15 BSGIE
■ 10.00-12.00 Working Group Digestive Pathology
■ 13.00-15.30 Working Group Digestive Pathology
■ 13.00-14.00 Young BASL
■ 14.10-15.10 Young BASL
■ 15.15-16.30 Young BASL
■ 09.00-10.30 BSGIE LIVE
■ 11.00-12.45 BSGIE LIVE
■ 14.00-15.00 Best of BWGE
■ 08.00-09.00 Symposium MSD
■ 9.00-09.50 BGDO
■ 09.50-10.00 Flash IPSEN
■ 10.00-10.50 BGDO
■ 10.50-11.20 Symposium SERVIER
■ 11.20-12.00 BGDO
■ 12.00-12.10 Flash EISAI/MSD
■ 12.10-12.55 BGDO
■ 14.00-16.00 BPC
| 3 |
08:30-12:10 - SESSION 1
Moderators : C. Van Kemseke (ULg), H. Piessevaux (UCL)
■ 08:30 Refractory benign esophageal strictures: repeated dilations, stenting, cutting? Christophe Snauwaert (AZ St Jan Brugge/UCL)
■ 08:55 Unexplained vomiting syndromes: cyclic vomiting, rumination syndrome, Functional vomiting, migraine… Jan Tack (KUL)
■ 09:20 Non-variceal upper gastro-intestinal bleeding. Maridi Aerts (VUB)
■ 09:45 Optimising medical treatment in IBD. Edouard Louis (ULG)
■ 10:10 BREAK
■ 10:30 Short bowel syndrome. Nutritional aspects and small bowel transplantation. Tim Vanuytsel (KUL)
■ 10:55 Small intestinal bacterial overgrowth (SIBO). Heiko De Schepper (UZA)
■ 11:20 Metabolic complications of bariatric surgery. Mariana Arvanitakis (ULB)
■ 11:45 Medical treatment of advanced neuro-endocrine tumours. Ivan Borbath (UCL)
■ 12:10 BREAK
13:15-16:55 - SESSION 2
Moderators : I. Colle (ASZ Aalst/UG), P. Roelandt (KUL)
■ 13:15 Auto-immune liver diseases: how application of scores can help in early Stratification.Xavier Verhelst (UG
■ 13:40 NAFLD: from diet to transplantation (and all what is in between). Sven Francque (UZA)
■ 14:05 Management of recurrent idiopathic acute pancreatitis. Pierre Deprez (UCL)
■ 14:30 Anticoagulants/anti-aggregants and therapeutic endoscopy. Arnaud Lemmers (ULB)
■ 14:55 BREAK
■ 15:15 Management of benign biliary and pancreatic strictures. Jean-Philippe Loly (ULg)
■ 15:40 Early diagnosis and treatment of cholangiocarcinoma. Rastislav Kunda (VUB)
■ 16:05 Obstructive defecation: conservative and/or surgical treatment? Bart van Geluwe (Kortrijk/KUL)
■ 16:30 Anal fissure: a pain in the ass… Danny De Looze (UG)
WE
DN
ES
DA
Y 0
3/
03
FR
ID
AY
0
5/
03
PG Course ROOM: GENT
PAVILLON 2
| 4 |
17:15-19:20 - SESSION
Moderators : J. Schouten (AZ Nikolaas, Sint-Niklaas), L. Vonghia (UZ Antwerpen)
■ 17:15 Introduction of the new Belgian ultrasound association. Jeoffrey Schouten (AZ Nikolaas, Sint-Niklaas), Luisa Vonghia (UZ Antwerpen)
■ 17:20 Ultrasound features in chronic and acute liver disease. Peter Michielsen (UZ Antwerpen)
■ 17:45 Ultrasound features of gallbladder and bile duct disorders. Jeoffrey Schouten (AZ Nikolaas, Sint-Niklaas)
■ 18:10 Benign and malignant liver tumours. Anja Geerts (UZ Gent)
■ 18:30 Contrast-enhanced ultrasound in 2021: ready to use in daily practice? Luisa Vonghia (UZ Antwerpen)
■ 18:55 Closing remarks Jeoffrey Schouten (AZ Nikolaas, Sint-Niklaas), Luisa Vonghia (UZ Antwerpen)
WE
DN
ES
DA
Y 0
3/
03
FR
ID
AY
0
5/
03
UltraSound Course ROOM: GENT
PAVILLON 2
PGCPOSTGRADUATE COURSE
| 5 |
14:00-15:50 - SESSION 1 : IBD BASIC
Moderators : C. Liefferinckx (ULB Erasme), J. P. Guedelha Sabino (UZ Leuven)
■ 14:00 I01 A discriminative metabolic profile in the sera of Crohn’s disease patients with fibrostenosis. S. Bos (1), M. De Vos (1), P. Hindryckx (2), T. Lobaton (2), L. Vanhaecke (1), D. Laukens (1) / [1] U Gent, [2] UZ Gent
■ 14:05 I02 Magnetization transfer MRI and T2-weighted MRI texture analysis allow non-invasive detection of intestinal fibrosis in a fibrosis-inducing chronic colitis mouse model. S. Bos (1), I. De Kock (2), L. Delrue (2), P. Hindryckx (2), M. De Vos (1), G. Villeirs (2), D. Laukens (1) / [1] U Gent, [2] UZ Gent
■ 14:10 Q&A
■ 14:15 I03 Blood proteins linked to immune tolerance, inflammation and cellular junctions reveal a succession of pathophysiological events preceding the relapse in Crohn’s disease patients stopping infliximab. N. Pierre (1), V. Huynh-Thu (1), M. Allez (2), Y. Bouhnik (3), D. Laharie (4), A. Bourreille (5), J. Colombel (6), M. Meuwis (1), E. Louis (1) / [1] U Liege, [2] Hôpital Saint Louis, Paris, France, [3] Hôpital Beaujon, Paris, France, [4] CHU Bordeaux, France, [5] CHU Hotel Dieu, Nantes, France, [6] Mt. Sinai Icahn School of Medicine, USA
■ 14:20 I04 Early prediction of response to vedolizumab in patients with active Inflammatory Bowel Disease: a prospective real-life multicentre cohort Study. C. De Galan (1), G. Gonzales (1), S. Van Welden (1), S. Tavernier (2), T. Lobaton (2), W. Van Moerkercke (3), B. Strubbe (4), H. Peeters (4), E. Macken (5), M. De Vos (1), D. Laukens (1), P. Hindryckx (2)/ [1] U Gent, [2] UZ Gent, [3] AZ Groeninge, Kortrijk, [4] AZ Sint-Lucas, Gent, [5] U Antwerpen
■ 14:25 Q&A
■ 14:30 Invited Lecture : Stromal cells in the pathogenesis of inflammatory bowel Disease. Michael Scharl (Zurich, Switzerland)
■ 14:45 Invited Lecture : JAK-STAT pathway targeting for the treatment of IBD. Silvio Danese (Milan, Italy)
■ 15:00 Invited Lecture : Transmembrane mucins MUC1 and MUC13 as novel players in mucosal barrier dysfunction in IBD. Annemieke Smet (Antwerp, Belgium)
■ 15:15 Q&A
■ 15:35 I05 Long-term environmental hypoxia does not impact experimental Crohn’s like ileitis. C. De Galan, S. Van Welden, T. Lobaton, P. Hindryckx, M. De Vos, D. Laukens / U Gent
■ 15:40 I06 Potential Role of Epithelial Protein Disulphide Isomerases in Crohn’s Disease Fibrosis. S. Vieujean (1), S. Hu (2), E. Bequet (2), C. Salee (2), C. Massot (2), N. Bletard (1), N. Pierre (2), F. Quesada Calvo (2), D. Baiwir (2), G. Mazzucchelli (2), E. De Pauw (2), C. Coimbra Marques (1), P. Delvenne (1), E. Louis (1), M. Meuwis (2) / [1] CHU Liège, [2] U Liege
■ 15:45 Q&A
■ 15:50 BREAK
WE
DN
ES
DA
Y 0
3/
03
FR
ID
AY
0
5/
03
IBD-BIRD ROOM: BRUSSELS
PAVILLON 1
| 6 |
16:05-18:30 - SESSION 2 : IBD CLINICAL
Moderators : E. Louis (ULg Liège), T. Lobaton Ortega (UZ Gent)
■ 16:05 I07 Ultraproactive therapeutic drug monitoring based on point-of-care testing of infliximab is not superior to reactive drug monitoring in patients with inflammatory bowel disease: 1 year results of a pragmatic clinical trial. P. Bossuyt (1), S. Claeys (2), S. D’haens (1), E. Hoefkens (1), B. Strubbe (1), D. Marichal (2), L. Pouillon (1), H. Peeters (2) / [1] Imelda GI Clinical Research Center, Bonheiden, [2] AZ Sint-Lucas, Gent
■ 16:10 I08 Quality improvement by benchmarking of a core outcome indicator set in inflammatory bowel disease: a multicentric feasibility study. P. Bossuyt (1), D. Baert (2), F. Baert (3), E. Hoefkens (1), I. Huys (2), N. Lembrechts (1), E. Jonckere (3), P. Dewint (2), L. Pouillon (1) / [1] Imelda Hospital, Bonheiden, [2] AZ Maria Middelares, Gent, [3] AZ Delta, Roeselare
■ 16:15 Q&A
■ 16:20 I09 Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unit. G. Dewitte, J. Geldof, M. Truyens, T. Lobaton / UZ Gent
■ 16:25 I10 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis. B. Verstockt (1), D. Alsoud (2), A. Outtier (1), J. Sabino (1), S. Vermeire (1), G. De Hertogh (1), M. Ferrante (1) / [1] UZ Leuven, [2] KULeuven
■ 16:30 Q&A
■ 16:35 I11 Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study. S. Vermeire (1), B. Feagan (2), E. Loftus Jr (3), S. Danese (4), W. Sandborn (5), T. Ritter (6), R. Mehta (7), U. Seidler (8), F. Seibold (9), I. Beales (10), H. Jong Kim (11), J. Mcnally (12), C. Yun (12), S. Zhao (12), X. Liu (12), C. Tasset (13), R. Besuyen (13), M. Watanabe (14), S. Schreiber (15), G. Rogler (16), T. Hibi (17), L. Peyrin-Biroulet (18)/ [1] UZ Leuven, [2] Western University, London, Canada, [3] Mayo Clinic, Rochester, USA, [4] Humanitas University, Milan, Italy, [5] University of California San Diego (UCSD), USA, [6] GI Alliance, Southlake, USA, [7] Surat Institute of Digestive Science, Gujarat, India, [8] Hannover Medical School, Germany, [9] Seibold & Partner Crohn’s Colitis Center, Bern, Switzerland, [10] Norfolk and Norwich University Hospital, UK, [11] Kyung Hee University Hospital, Seoul, Korea, [12] Gilead Sciences Inc, USA, [13] Galapagos NV, [14] Tokyo Medical and Dental University, Tokyo, Japan, [15] University Medical Center Schleswig-Holstein, Kiel, Germany, [16] University Hospital, Zurich, Switzerland, [17] Kitasato Institute Hospital, Tokyo, Japan, [18] Nancy University Hospital, Vandoeuvre-lès-Nancy, France
■ 16:40 I12 Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately-Severely Active Ulcerative Colitis: Phase 2b/3 SELECTION Study. S. Vermeire (1), L. Peyrin-Biroulet (2), E. Loftus Jr (3), S. Danese (4), W. Sandborn (5), R. Fogel (6), S. Nijhawan (7), R. Kempinski (8), R. Filip (9), I. Hospodarsky (10), J. Mcnally (11), C. Yun (11), S. Zhao (11), X. Liu (11), C. Tasset (12), R. Besuyen (12), M. Watanabe (13), S. Schreiber (14), G. Rogler (15), T. Hibi (16), B. Feagan (17) / [1] UZ Leuven, [2] Nancy University Hospital, Vandoeuvre-lès-Nancy, France, [3] Mayo Clinic, Rochester, USA, [4] Humanitas Clinical and Research Cente, Milan, Italy, [5] University of California San Diego (UCSD), USA, [6] Clinical Research Institute of Michigan, Chesterfield, USA, [7] SMS Medical College Hospital, Jaipur, India, [8] Wroclaw Medical University, Poland, [9] Clinical Hospital No.2, Rzeszów, Poland, [10] Ternopil National Medical University, Ternopil Oblast, Ukraine, [11] Gilead Sciences Inc, USA, [12] Galapagos NV, [13] Tokyo Medical and Dental University, Tokyo, Japan, [14] University Medical Center Schleswig-Holstein, Kiel, Germany, [15] University Hospital, Zurich, Switzerland, [16] Kitasato Institute Hospital, Tokyo, Japan, [17] Western University, London, Canada
WE
DN
ES
DA
Y 0
3/
03
FR
ID
AY
0
5/
03
IBD-BIRD ROOM: BRUSSELS
PAVILLON 1
| 7 |
■ 16:45 Q&A
■ 16:50 Invited Lecture : Intestinal Ultrasound in IBD: what is the Current Evidence? Christian Maaser (Lüneburg, Germany)
■ 17:05 Invited Lecture : Stricturoplasy, is there still any Place for Resections? André d’Hoore (UZ Leuven)
■ 17:20 Invited Lecture : Adolescents and Young Adults with Crohn’s Disease: Health Literacy and Transition of Care. Els Van De Vijver (UZ Antwerpen) & Gigi Veereman (UZ Brussel)
■ 17:35 Q&A
■ 17:55 K01 First experiences with Modulife® in inducing remission in pediatric Crohn patients in Belgium. E. Snoeck (1), E. Van De Vijver (2), A. Van Gils (2), N. Moes (2), I. Hoffman (3), B. Hauser (4), G. Veereman (4), R. De Bruyne (1), S. Van Biervliet (1), M. Van Winckel (1), S. Vande Velde (1) / [1] UZ Gent, [2] UZ Antwerpen, [3] UZ Leuven, [4] VUB, Jette
■ 18:00 I13 Positioning strictureplasty in the treatment of extensive Crohn’s disease ileitis. A comparative study with ileocecal resection. G. Bislenghi (1), S. Fieuws (2), A. Wolthuis (1), D. Vanbeckevoort (1), J. Sabino (1), M. Ferrante (1), S. Vermeire (1), A. D’hoore (1) / [1] UZ Leuven, [2] KU Leuven
■ 18:05 Q&A
■ 18:10 I14 Evaluation of trough level and disease activity after switch from adalimumab originator (Humira®) to biosimilar (Imraldi®) in patients with inflammatory bowel disease: 6 months interim analysis of the SafE-OrBi study. N. Deprez (1), T. De Somer (2), D. Baert (2), M. Deceuninck (3), I. Huys (4), V. Mattens (5), A. Sterckx (5), S. Vanden Branden (5), E. Vanderstraeten (2), J. Vandervoort (5), N. Van Heddegem (2), P. Dewint (2) / [1] U Gent, [2] AZ Maria Middelares, Gent, [3] Sint Vincentius Deinze, [4] Maria Middelares Ziekenhuis, Gent, [5] OLV Aalst
■ 18:15 I15 Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator (Humira®) to biosimilar (Imraldi®) in patients with inflammatory bowel disease: 6-month interim analysis of the SafE-OrBi study. T. De Somer (1), N. Deprez (2), D. Baert (1), M. Deceuninck (3), I. Huys (1), V. Mattens (4), A. Sterckx (4), S. Vanden Branden (4), E. Vanderstraeten (1), J. Vandervoort (4), N. Van Heddegem (1), P. Dewint (1) / [1] AZ Maria Middelares, Gent, [2] U Gent, [3] Sint Vincentius Deinze, [4] OLV Aalst
■ 18:20 Q&A
■ 18:25 Award Ceremony, Closing Remarks
■ 18:30 General Assembly of the Scientific Group
WE
DN
ES
DA
Y 0
3/
03
FR
ID
AY
0
5/
03
IBD-BIRD ROOM: BRUSSELS
PAVILLON 1
| 8 |
08:30-10:00 - SESSION 1
Moderators : J. Delwaide (CHU Liège), T. Vanwolleghem (UZ Antwerpen)
■ 08:30 A01 The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study. J. De Graeve, T. Delvaeye, S. De Lepeleere, T. De Somer, C. Van Steenkiste / Maria Middelares Ziekenhuis, Gent
■ 08:40 A02 NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma. H. Degroote (1), A. Vandierendonck (2), B. Vanderborght (2), X. Verhelst (1), A. Geerts (1), L. Devisscher (2), H. Van Vlierberghe (1) / [1] UZ Gent, [2] U Gent
■ 08:50 A03 Human and mouse precision-cut liver slices as a dynamic tool to model liver fibrosis. Dewyse (1), V. De Smet (1), H. Reynaert (2), L. Van Grunsven (1) / [1] VUB Brussel, [2] UZ Brussel
■ 09:00 A04 Hypoxia-induced angiogenesis rescues survival upon extended hepatectomy in mice. M. De Rudder (1), A. Dili (2), B. Pirlot (1), C. Bouzin (1), I. Leclercq (1) / [1] UCL Brussels, [2] CHU UCL Namur
■ 09:10 A05 Intensive lifestyle management improves steatosis and fibrosis in pediatric non-alcoholic fatty liver disease. S. Lefere (1), E. Dupont (2), K. De Boeck (2), A. De Guchtenaere (1), S. Van Biervliet (1), S. Vande Velde (1), X. Verhelst (1), L. Devisscher (1), H. Van Vlierberghe (1), A. Geerts (1), R. De Bruyne (1) / [1] U Gent, [2] Zeepreventorium, De Haan
■ 09:20 A06 Relative in vivo antiviral potency of pegIFN-lambda vs -alpha against HEV. G. Sari (1), C. Mulders (1), M. Van De Garde (1), J. Zhu (2), G. Van Oord (1), Z. Feng (2), J. Kreeft-Voermans (2), A. Boonstra (1), T. Vanwolleghem (3) / [1] U Erasmus MC Rotterdam, The Research Institute, Ohio, USA, [2] UZA Antwerpen
Moderator : I. Borbath (UCL Saint-Luc, Brussels)
■ 09:30 Brohée lecture: Advances in the approach to pulmonary vascular complications of liver disease. Sarah Raevens (UZ Gent)
■ 10:30 BREAK
FR
ID
AY
0
5/
03
BASL-BLIC ROOM: ANTWERP
PAVILLON 1
■ 10:00 - 10:30 Satellite Symposium EISAI / MSD: Crowded HCC treatment landscape and busy COVID-19 times: where does lenvatinib stand? Speaker: Willem Lybaert /
AZ Nikolaas – AZ Lokeren – UZ Antwerpen/
TH
UR
SD
AY
0
4/
03
| 9 |
10:45-11:15
Moderator : D. Ysebaert (UZ Antwerpen)
■ 10:45 BELIAC lecture : COVID-19 in liver transplant patients and liver candidates -what have we learnt so far? Wojtek Polak / Erasmus MC, Rotterdam, The Netherlands
11:15-12:40 - SESSION 2
Moderators : A. Geerts (UZ Gent), T. Gustot (ULB Erasme)
■ 11:15 A07 Restoration of altered bile acid pool inhibits the development of nonalcoholic steatohepatitis. J. Gillard (1), A. Tailleux (2), C. Sempoux (3), B. Staels (2), L. Bindels (1), I. Leclercq (1) / [1] UC Louvain, [2] University of Lille, France, [3] CHUV Lausanne, Switzerland
■ 11:27 A08 Multicellular primary mouse liver spheroids for DILI, MAFLD and fibrosis studies. E. Van Os, L. Cools, N. Eysackers, A. Smout, S. Verhulst, I. Mannaerts, L. Van Grunsven / VUB Brussel
■ 11:39 A09 Acute liver decompensation following bariatric surgery in patients without cirrhosis: clinical presentation, histological findings and management. P. Vande Berg (1), A. Ulaj (1), G. De Broqueville (1), M. De Vos (2), B. Delire (1), P. Hainaut (1), J. Thissen (1), P. Stärkel (1), P. Henry (1), M. Komuta (1), N. Lanthier (1) / [1] UC Louvain, [2] Hôpital Jolimont, Haine-Saint-Paul
■ 11:51 A10 Altered gut adaptive immune surveillance favors microbial translocation and correlate with progressive alcoholic liver disease in humans. L. Maccioni (1), B. Pirlot (1), I. Leclercq (1), Y. Horsmans (1), B. Schnabl (2), P. Stärkel (1) / [1] UC Louvain, [2] University of California San Diego, USA
■ 12:03 A11 Feasibility of systemic treatment after progression following radioembolization in patients with hepatocellular carcinoma: a retrospective cohort study. C. Van Laeken , S. Cappuyns, G. Maleux, V. Vandecaveye, C. Verslype, C. Deroose, J. Dekervel / UZ Leuven
■ 12:15 A12 Muscle fat content is strongly associated with NASH and decreases upon NASH resolution: a longitudinal biopsy-proven study in obese patients. M. Nachit (1), W. Kwanten (2), J. Thissen (1), B. Op De Beeck (2), L. Van Gaal (2), L. Vonghia (2), A. Verrijken (2), A. Driessen (2), Y. Horsmans (3), I. Leclercq (1), S. Francque (2). / [1] UCL, [2] UZ Antwerpen, [3] UCL Saint-Luc, Brussels
■ 12:27 A13 A profibrotic role for the orphan G-protein coupled receptor 176 during hepatic stellate cell activation. V. De Smet (1), S. Verhulst (1), L. Dewyse (1), M. Kazemzadeh Dastjerd (1), G. Halder (2), I. Mannaerts (1), L. Van Grunsven (1) / [1] VUB Brussel, [2] KU Leuven
■ 12:40 BREAK
BASL-BLIC ROOM: ANTWERP
PAVILLON 1T
HU
RS
DA
Y 0
4/
03
| 10 |
13:20-14:00
Moderator : F. Nevens (UZ Leuven)
■ 13:20 Marc Hautekeete Lecture : NaMELD: impact on liver transplantation and survival on waiting list. Hans De Ferrante / The Netherlands
14:30-15:45 - SESSION 3
Moderators : E. Trepo (ULB), D. Ysebaert (UAntwerpen)
■ 14:30 A14 Contribution of monocytes to systemic inflammation in alcohol use disorder patients. J. Kasavuli, L. Maccioni, B. Pirlot, I. Leclercq, P. Stärkel / UCL Brussels
■ 14:40 A15 Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models. H. Degroote (2), S. Lefere (1), A. Vandierendonck (1), B. Vanderborght (1), T. Meese (1), F. Van Nieuwerburgh (1), X. Verhelst (2), A. Geerts (2), H. Van Vlierberghe (1), L. Devisscher (1) / [1] U Gent, [2] UZ Gent
■ 14:50 A16 Has the 5-year mortality of patients with alcoholic cirrhosis changed during the last 20 years? ... The reality is that patients die just as much, but in a different way. E. Kaze, J. Henrion / Centres Hospitaliers Jolimont
■ 15:00 A17 Comparison of clinic-biochemical risk scores versus ultrasound for steatosis detection in subjects with type 1 diabetes. J. Mertens, J. Weyler, E. Dirinck, L. Vonghia, L. Mortelmans, C. De Block, S. Francque / UZ Antwerpen
■ 15:10 A18 The prevalence of NAFLD in a cohort of type 1 diabetes subjects based on non-invasive assessment and its association with macrovascular complications. J. Mertens, J. Weyler, E. Dirinck, L. Mortelmans, L. Vonghia, C. De Block, S. Francque / UZ Antwerpen
■ 15:20 A19 The effects of oral bosentan treatment on the increased intrahepatic vascular resistance and disease severity in high fat high fructose diet-fed Zucker fatty rats with hepatic steatosis. D. Van Der Graaff (1), W. Kwanten (2), J. De Man (1), B. De Winter (1), L. Vonghia (2), S. Francque (2) / [1] U Antwerpen, [2] UZ Antwerpen
■ 15:30 BASL Best Basic and Clinical Prize
■ 15:45 BASL General Assembly
BASL-BLIC ROOM: ANTWERP
PAVILLON 1
■ 14:00 - 14:30 Satellite Symposium ALNYLAM: Unexplained severe diffuse abdominal pain, don’t miss the Diagnosis. Speaker: Prof. D. Cassiman, UZ Leuven
TH
UR
SD
AY
0
4/
03
| 11 |
FR
ID
AY
0
5/
03
Case Report ROOM: BRUSSELS
TH
UR
SD
AY
0
4/
03
PAVILLON 1
09:00-10:15 - SESSION 1
Moderators : D. De Looze (UZ Gent), C. Vankemseke (CHU Liège)
■ 09:00 C01 Purtscher’s-like retinopathy associated with acute alcoholic pancreatitis, a case report. F. Anné (1), D. Coevoet (1), W. Verlinden (2) / [1] UGent, [2] AZ Nikolaas
■ 09:15 C02 A case of Secukinumab induced inflammatory bowel disease. E. Pollet, K. Plovie, L. Bossuyt, G. Deboever, M. Cool, G. Lambrecht / AZ Damiaan, Oostende
■ 09:30 C03 Cardiogenic Shock due to Mesalazine-induced Myocarditis in a Patient with Ulcerative Colitis: A Case Report. C. Severi, M. Struyve / Ziekenhuis Oost Limbug (ZOL), Genk
■ 09:45 C04 Erythema multiforme in the esophagus. J. Vandewalle (1), P. Van Eyken (2), M. Struyve (2) / [1] KU Leuven,[2] Ziekenhuis Oost Limbug (ZOL), Genk
■ 10:00 C05 Endoscopic lithotripsy for Bouveret syndrome complicated postoperatively by small bowel obstruction from gallstone fragments. R. Huynh (1), J. Rabindran (2), D. Goonawardhana (2), G. Becerril-Martinez (2) / [1] University of New South Wales, Sydney, Australia, [2] Concord Repatriation General Hospital, Concord, Australia
■ 10:15 BREAK
10:30-11:45 - SESSION 2
Moderators : D. De Looze (UZ Gent), C. Vankemseke (CHU Liège)
■ 10:30 C06 EUS-guided radiofrequency ablation for a left adrenal oligometastasis of a gastric adenocarcinoma. M. Figueiredo Ferreira, L. Mans, J. Deviere, J. Van Laethem / CUB ULB Erasme
■ 10:45 C07 Rapid deterioration of a patient in the Emergency Room: No time to waste! N. Thelinge MD (1), M. Abasbassi MD (2), L. Nuyten MD, F. (2), De Burghgraeve (2), T. Verhamme MD (2), M Cool MD (2), G. Deboever (2), G. Lambrecht MD (2)/ [1] KU Leuven [2] AZ Damiaan
■ 11:00 C08 An unexpected rectal mass. T. De Somer (1), A. Jauregui Amezaga (2), N. Komen (2), B. Op De Beeck (2), T. Jardinet (2), H. De Schepper (2) / [1] Maria Middelares Ziekenhuis, Gent, [2] UZ Antwerpen
■ 11:15 C09 Gastric amyloidosis: unusual cause of massive upper digestive bleeding. B. Deressa, L. Poelmans, R. Bestman, F. Lockefeer, O. Peters / Monica, Deurne
■ 11:30 C10 Unusual cause of low abdominal pain: colon perforation due to a spontaneous migration of an intrauterine device. F. Gelders (1), J. Vandewalle (1), M. Struyve (2) / [1] UZ Leuven, [2] Ziekenhuis Oost Limbug (ZOL), Genk
| 12 |
FR
ID
AY
0
5/
03
BeSPGHAN ROOM: BRUSSELS
TH
UR
SD
AY
0
4/
03
PAVILLON 1
■ 13:00-14:00 General Assembly BeSPGHAN
14:00-15:10 - SESSION 1
Moderators : I. Paquot (CHC Liège), P. Alliet (Jessa Hasselt)
■ 14:00 Invited Lecture : To biopsy or not – new ESPGHAN recommendations for celiac disease. S. Collinet / CHC Liège
■ 14:25 K02 Child with protein losing enteropathy as presentation of collagenous duodenitis and eosinophilic gastroenteritis. M. De Keukelaere (1), K. Van Hoeve (2), I. Hoffman (2) / [1] Imelda Hospital, Bonheiden, [2] UZ Leuven
■ 14:35 Invited Lecture : New ESPGHAN guidelines for feeding psychomotor impaired patients. K. Huysentruyt / KHC UZ Brussel
■ 15:00 K03 Is there a correlation between symptoms suggestive for gastroparesis and results of gastric emptying breath test in children? B. Hauser, K. Huysentruyt, G. Veereman, E. De Greef, T. Devreker, Y. Vandenplas / KHC UZ Brussel
■ 15:40 BREAK
15:50-17:00 - SESSION 2
Moderators : I. Hoffman (UZ Leuven), S. Vande Velde (UZ Gent)
■ 15:50 Invited Lecture : Modulen/Modulife: a cost effective therapy in Crohn’s disease.F. Smets /UCL Brussels, S. Vande Velde / U Gent.
■ 16:10 K04 Development of a clinical risk score for signifi cant liver fi brosis in pediatric non-alcoholic fatty liver disease. S. Lefere (1), E. Dupont (2), K. De Boeck (2), A. De Guchtenaere (3), S. Van Biervliet (3), S. Vande Velde (3), X. Verhelst (1), L. Devisscher (3), H. Van Vlierberghe (1), A. Geerts (1), R. De Bruyne (3) / [1] U Gent, [2] Zeepreventorium, De Haan, [3] UZ Gent
■ 16:20 Invited Lecture : Is a vegan diet feasible in childhood?T. Bosmans / KU Leuven
■ 16:50 K05 Towards automated scoring of stool consistency in diapers using a digital tool. K. Huysentruyt (1), L. Thomas (2), Y. Vandenplas (1) / [1] KidZ Health Castle, UZ Brussel, [2] Danone, Utrecht, Netherlands (the), Nutricia Research
■ 15:10 - 15:40 Satellite Symposium ABBVIE:Multidisciplinary clinic for care and transition of children and adolescents with IBDSpeaker: Prof. Veereman / UZ Brussel
| 13 |
FR
ID
AY
0
5/
03
GIREM ROOM: GENT
TH
UR
SD
AY
0
4/
03
08:30-10:25 - SESSION 1
Moderators : W. Boesmans (Hasselt University), G. Matteoli (KU Leuven)
■ 08:30 Invited Lecture : Neuronal diversity in the enteric nervous system – from development to circuits. U. Marklund (Karolinska Institutet, Stockholm, Sweden)
■ 09:15 B01 Enteric glia cell and macrophage interaction in health and disease. L. Van Baarle (1), S. Abdu Rahiman (1), M. Stakenborg (1), V. De Simone (1), S. Ibiza Martinez (2), G. Matteoli (1) / [1] KU Leuven, [2] U Antwerpen
■ 09:30 B02 Extracting neuronal activity signals from ENS microscopy recordings of contractile tissue: a cell tracking approach using B-spline Explicit Active Surfaces (BEAS). Y. Kazwiny (1), J. Pedrosa (2), Z. Zhang (1), W. Boesmans (3), J. D’hooge (1), P. Vanden Berghe (1) / [1] KULeuven, [2] INESC TEC, Portugal, [3] Hasselt University
■ 09:45 B03 The enteric nervous system (ENS) responds to host-derived and bacterial amyloids by activating a pro-inflammatory gene circuit. P. Verstraelen, N. De Loose, R. Verboven, S. Van Remoortel, W. De Vos, J. Timmermans / U Antwerp
■ 10:00 B04 Study on the role of muscularis macrophages in aging-associated neurodegeneration and constipation. M. Viola, M. Chavero Pieres, N. Stakenborg, E. Modave, N. Fabre, I. Appeltans, J. Van Herck, A. Sifrim, G. Boeckxstaens / KU Leuven
■ 10:15 B05 Pitch : Tyramid-amplified immunostaining reveals amyloid in the gut. R. Verboven, P. Verstraelen, S. Van Remoortel, W. De Vos, J. Timmermans / U Antwerpen
■ 10:20 B06 Pitch : Dissecting TLR-mediated immune responses to amyloids in the enteric nervous system. N. De Loose, P. Verstraelen, S. Van Remoortel, J. Timmermans, W. De Vos / U Antwerpen
■ 10:25 BREAK
10:45-12:35 - SESSION 2
Moderators : A. Smet (U Antwerp), T. Vanuytsel (KU Leuven)
■ 10:45 B07 Characteristics of a population visiting a patient centred informative website: prevalence of Rome IV criteria for irritable bowel syndrome and red flag symptoms. K. Van Malderen, J. De Man, B. De Winter, H. De Schepper / U Antwerpen
■ 11:00 B08 Aerosol-generating and droplet spread in nasogastric intubation in the COVID-19 era. I. Huang (1), W. Verbeure (1), A. Geeraerts (1), L. Timmermans (2), J. Tóth (1), H. Geysen (1), L. Cools (1), F. Carbone (1), J. Schol (1), H. Devriese (2), R. Haesaerts (2), H. Mori (1), T. Vanuytsel (2), J. Tack (1) / [1] KULeuven, [2] UZ Leuven
■ 11:15 B09 Bismuth-based vs. standard triple therapy for the eradication of Helicobacter pylori in Belgium: final results of a multicentre, non-blinded randomized, prospective study. François S. (1), Mana F. (2), Saminou R. (3), Lamy V. (4), Cadranel S. (5), Bontems P. (5), Miendje Deyi V. (3), Macken E. (6), Kindt S. (1) / [1] UZ Brussel, [2] Sint-Jan, Brussel, [3] ULB Saint-Pierre, [4] CHU Charleroi, [5] ULB HUDERF, [6] UZ Antwerpen
PAVILLON 2
| 14 |
FR
ID
AY
0
5/
03
GIREM ROOM: GENT
TH
UR
SD
AY
0
4/
03
■ 11:30 B10 Duodenal mucosal gene expression is associated with duodenal permeability and affected by proton pump inhibitor therapy in functional dyspepsia. M. Ceulemans (1), L. Wauters (1), K. Geboers (1), A. Accarie (1), J. Toth (1), G. De Hertogh (2), J. Tack (1), T. Vanuytsel (1) / [1] KU Leuven, [2] UZ Leuven
■ 11:45 B11 Prevalence of double incontinence in patients with fecal incontinence and associated factors. M. Surmont, B. Roossens, S. Kindt / UZ Brussel
■ 12:00 B12 Efficacy of a new approach to the reintroduction phase of the low-FODMAP diet in IBS patients. Z. Mariën (1), K. Van Den Houte (1), E. Colomier (1), J. Schol (1), J. Van Den Bergh (2), J. Vanderstappen (2), N. Pauwels (2), C. Matthys (2), T. Vanuytsel (2), F. Carbone (1), J. Tack (2) / [1] KU Leuven, [2] UZ Leuven
■ 12:15 B13 Efficacy and safety of spore-forming probiotics in functional dyspepsia: a randomised placebocontrolled trial. L. Wauters (1), M. Ceulemans (2), K. Geboers (1), J. Toth (2), D. Walgraeve (3), W. Thys (4), R. Dybajlo (5), J. Tack (1), T. Vanuytsel (1) / [1] UZ Leuven, [2] KU Leuven, [3] Jessa Ziekenhuis, Hasselt, [4] MY RESEARCH, Diepenbeek, [5] MY HEALTH, Kermt
■ 12:30 B14 Pitch : Symptoms and duodenal mucosal integrity and are improved by a dietary intervention in functional dyspepsia. K. Van Den Houte (1), F. Carbone (1), J. Toth (1), Z. Mariën (1), K. Haugen Sandvik (1), J. Schol (1), E. Colomier (1), J. Van Den Bergh (2), J. Vanderstappen (2), N. Pauwels (2), C. Matthys (2), T. Vanuytsel (2), J. Tack (2) / [1] KU Leuven, [2] UZ Leuven
■ 12:35 BREAK
13:30-15:00 - SESSION 3
Moderators : L. Devisscher (U Gent), R. Farré (KU Leuven)
■ 13:30 B15 Aberrant MUC13 expression as prognostic marker for gastric cancer. B. Oosterlinck (1), T. Breugelmans (1), J. De Man (1), K. Geboes (2), J. Kupcinskas (3), A. Link (4), B. De Winter (1), A. Smet (1) / [1] U Antwerpen, [2] UZ Gent, [3] Lithuanian University of Health Sciences, Kaunas, Lithuania, [4] Otto von Guericke University Magdeburg, Germany
■ 13:45 B16 A role for short-chain fatty acids in the disruption of the circadian clock during chronic jetlag? L. Desmet, T. Thijs, A. Segers, R. Mas, K. Verbeke, I. Depoortere / KULeuven
■ 14:00 B17 Disruption of the gut-liver axis in experimental sclerosing cholangitis and colitis triggers compositional and phenotypical changes in hepatic myeloid cell subsets. K. De Muynck, T. Meese, B. Vanderborght, S. Lefere, A. Geerts, X. Verhelst, F. Van Nieuwerburgh, H. Van Vlierberghe, L. Devisscher / U Gent
■ 14:15 B18 Unpredictable early life adversity in female rats disrupts the epigenetic regulation of stress-induced visceral pain in adulthood. T. Louwies, B. Greenwood-Van Meerveld / Oklahoma University Health Sciences Center, Oklahoma City, USA
■ 14:30 Invited Lecture : Mechanisms of Stress-Induced Visceral Pain. B. Greenwood-Van Meerveld (Oklahoma University, USA)
■ 15:00 Closing remarks
PAVILLON 2
| 15 |
FR
ID
AY
0
5/
03
BSGIE ROOM: LIEGE
TH
UR
SD
AY
0
4/
03
Part 01
Moderator : C. Snauwaert (AZ Sint-Jan Brugge-Oostende, Brugge / UCL Saint-Luc, Brussels)
■ 14:00 IntroductionRaf Bisschops, BSGIE President
■ 14:05 Invited Lecture : POEM for esophageal achalasia.Haruhiro Inoue / Digestive Disease Center, Showa University Koto Toyosu Hospital Japan
14:30-15:10 - SESSION 1 : OUTCOMES OF ENDOSCOPIC THERAPY
Moderators : P. Eisendrath (ULB Saint-Pierre, Brussels), P. Deprez (UCL Saint-Luc, Brussels), S. Van Langendonck (AZ Maria Middelares, Gent)
■ 14:30 G01 Prevalence and detection of early adverse events following POEM in a single-center patient cohort – why performing post-procedural imaging or endoscopy can be omitted. Nullens S., Oude Nijhuis R., Oors J., Bastiaansen B., Fockens P., Bredenoord A. / Academic Medical Center, Amsterdam, The Netherlands
■ 14:36 G02 Impact of endoscopic duodenal and ampullary resection in familial adenomatous polyposis patients: Spigelman classifi cation can be considered as outdated due to a low risk of invasive cancer in patients with regular follow-up and endoscopic resection, even in stage III and IV.Belhassine M. (1), Pérez-Cuadrado Robles E. (2), Leonard D. (3), Kartheuser A. (3), Karin D. (3), Hélène D. (3), Deprez P. (1) / [1] UCL Saint-Luc, Brussels, [2] Hôpital EuropéenGeorges Pompidou, Paris, France, [3] UCL Saint-Luc, Brussels
■ 14:42 G03 Endoscopic dilation of post-sleeve gastrectomy stenosis: long-term effi cacy and safety results.Lorenzo D., Gkolfakis P., Lemmers A., Louis H., Huberty V., Blero D., Devière J. / ULB Erasme, Brussels
■ 14:48 G04 Pneumatic balloon dilation for the treatment of post-fundoplication symptoms: long-term effi cacy and safety results. Gkolfakis P., Lorenzo D., Blero D., Louis H., Lemmers A., Arvanitakis M., Pierre E., Devière J. / ULB Erasme, Brussels
■ 14:54 G05 Endoscopic mucosal resection of colorectal polyps: results, adverse events and two-year outcome.Chaoui I., Demedts I., Roelandt P., Willekens H., Bisschops R. / UZ Leuven
■ 15:00 Discussion
PAVILLON 2
■ 13:30 - 14:00 Satellite Symposium MEDTRONIC: SEDATION IN ENDOSCOPYManaging the risks of conscious sedation for enhanced patient safety. Speakers: Prof. Dr. Bisschops, Prof. Dr. Van de Velde
| 16 |
FR
ID
AY
0
5/
03
BSGIE ROOM: LIEGE
TH
UR
SD
AY
0
4/
03
PAVILLON 2
15:10-15:36 - SESSION 2 : BILIO-PANCREATIC ENDOSCOPY
Moderators : P. Hindryckx (UZ Gent), A. Lemmers (ULB Erasme, Brussels), M. Struyve (Ziekenhuis Oost-Limburg, Genk)
■ 15:10 G06 Pre-procedural Imaging Does not Predict Technical Failure of EUS- guided Intrahepatic Biliary Drainage: Post-hoc Analysis from a Large Retrospective Cohort. Bronswijk M. (1), Vanella G. (2), Van Der Merwe S. (1) / [1] UZ Leuven, [2] IRCCS San Raffaele Scientific Institute, Milan, Italy
■ 15:16 G07 Biliary and pancreatic endoscopy in patients with previous Whipple’s duodenopancreatectomy: Is enteroscopy-assisted ERCP the first choice? Garcés-Duran R., Monino L., Deprez P., Piessevaux H., Moreels T. / UCL Saint-Luc, Brussels
■ 15:22 G08 Endoscopic management of biliopancreatic pathology in patients with Roux-en-Y gastric bypass: lessons learned from multiple options. Monino L., Garces-Duran R., Piessevaux H., Deprez P., Moreels T. / UCL Saint-Luc, Brussels
■ 15:28 G09 About the diagnosis and treatment of suspected bile duct pathology in Roux-en-Y liver transplant patients. Moreels T., Monino L., Dahlqvist G., Delire B., Coubeau L., Ciccarelli O., Bonaccorsi Riani E., Goffette P., Sokal E., Piessevaux H. / UCL Saint-Luc, Brussels
■ 15:36 Discussion
Part 02
Moderator : E. Toussaint (CHU Charleroi / ULB Erasme, Brussels)
15:46-16:43 - SESSION 3 : IMPROVING QUALITY IN ENDOSCOPY
Moderators : T. Moreels (UCL Saint-Luc, Brussels), M. Aerts (UZ Brussel, Brussels), G. Rasschaert (UZ Brussel, Brussels)
■ 15:46 G10 Computer Aided Detection (CADe) in colonoscopy: an end-user experience using two systems. Van Langendonck S. (1), Corens P. (2), Stragier E. (3) Vanderstraeten E. (1), Walgraeve D. (3), Bouhadan S. (2), Dewint P. (1) / [1] Maria Middelares Ziekenhuis, Gent, [2] UZ Antwerpen, [3] Jessa Ziekenhuis, Hasselt
■ 15:52 G11 Semi-automated annotation tool outperforms trained medical students and is comparable to clinical expert performance for frame level detection of colorectal polyps. Eelbode T. (1), Ahmad O. (2), Sinonquel P. (3), Kocadag T. (2), Narayan N. (2), Rana N. (2), Maes F. (1), Lovat L. (2), Bisschops R. (3) / [1] KU Leuven, [2] University College London Hospitals, London, UK, [3] UZ Leuven
■ 15:58 G12 Implementation of Aldrete’s scoring system significantly reduces recovery time after procedural sedation by more than 20%. Roelandt P. (1), Haesaerts R. (1), Missotten R. (2), Desmet E.(2), Demedts I. (1), Bisschops R. (1) / [1] UZ Leuven, [2] KU Leuven
| 17 |
FR
ID
AY
0
5/
03
BSGIE ROOM: LIEGE
TH
UR
SD
AY
0
4/
03
PAVILLON 2
■ 16:04 G13 Assessment of the clinical impact of postponing endoscopic procedures using risk stratification during COVID-19 pandemic: a prospective systematic multicentric study. Ouazzani S. (1), Golfakis P. (1), Lemmers A. (1), Blero D. (1) Eisendrath P. (2), Deviere J. (1) / [1] ULB Erasme, Brussels, [2] ULB Saint-Pierre, Brussels
■ 16:10 Discussion
■ 16:20 Invited Lecture : Endoscopic management of gastrointestinal motility disorders: ESGE guidelines Bas WEUSTEN / Utrecht, The Netherlands
16:45-17:15 - SESSION 4 : INNOVATIONS IN THERAPEUTIC ENDOSCOPY
Moderators : P. Dewint (AZ Maria Middelares, Gent / UZ Antwerpen), P. Deprez (UCL Saint-Luc, Brussels), Y. Mourabit (ULB Erasme, Brussels)
■ 16:45 G14 Laparoscopic versus EUS-guided Gastroenterostomy for Gastric Outlet Obstruction: An International Multicenter Propensity Score-Matched Comparison. Bronswijk M. (1), Vanella G. (2), Van Malenstein H. (3), Laleman W. (3), Jaekers J. (3), Topal B. (4), Daams F. (4), Besselink M. (4), Arcidiacono P. (2), Voermans R. (4), Fockens P. (4), Larghi A. (2), Van Wanrooij R. (4), Van Der Merwe S. (3) / [1] Imelda General Hospital, Bonheiden, [2] IRCCS San Raffaele Scientific Institute, Milan, Italy, [3] UZ Leuven, [4] UMC, Amsterdam, Netherlands (the)
■ 16:51 G15 Technique, safety and feasibility of EUS-guided radiofrequency ablation of pancreatic tumors and oligo-metastatic disease: an observational, prospective multicenter registry. Figueiredo Ferreira M. (1), Hindryckx P. (2), Eisendrath P. (3), Deviere J. (1), Deprez P. (4), Monino L. (4), Van Laethem J. (1), Borbath I. (4) / [1] ULB Erasme, Brussels, [2] UZ Gent, [3] ULB Saint-Pierre, Brussels, [4] UCL Saint-Luc, Brussels
■ 16:57 G16 Magnetic Gastrointestinal Universal Septotome: first results of a pilot study in Epiphrenic Esophageal Diverticulum. Blero D. / ULB Erasme, Brussels
■ 17:03 G17 Endoscopic management of buried bumper syndrome: the Balloon Dilation Pull (BDP) technique: a case series. Maly M., Snauwaert C. / AZ Sint-Jan Brugge-Oostende
■ 17:09 Discussion
■ 17:15 Award Ceremony Best abstract & best presentation
| 18 |
10:00-12:00 - SESSION 1
Moderators : A. Hoorens (UZ Gent), N. D’Haene (ULB Erasme, Brussels)
■ 10:00 R01 A unique case of duodenal mass requiring pancreaticoduodenectomy: giant Brunner’s gland hamartoma. K. Paquet (1), I. Van Den Berghe (2) / [1] KULeuven, [2] AZ Sint-Jan Brugge-Oostende
■ 10:15 R02 Automatic embedding technique for histopathological examination results in increased R0 resection rates for endoscopic submucosal dissection. L. Verset (1), A. Bucalau (2), M. Figueiredo (2), J. Devière (2), V. Huberty (2), P. Demetter (1), A. Lemmers (2) / [1] ULB Bordet, Brussels, [2] ULB Erasme, Brussels
■ 10:30 R03 Pancreatic medullary carcinoma developed on a Pancreatic Intraductal Papillary Mucinous Neoplasm with loss of MSH2 and MSH6 expression. C. Verocq (1), M. Racu (1), D. Bafort (2), G. Butorano (2), L. Perez-Casanova Gomez (1), J. Navez (1), M. Witterwulghe (3), K. Sheahan (4), N. Swan (4), J. Closset (1), J. Van Laethem (1), C. Maris (1), N. D’haene (1) / [1] ULB Erasme, Brussels, [2] CurePath,Charleroi, [3] CHIREC, Brussels, [4] St. Vincent’s University Hospital, Dublin, Ireland, Pathology
■ 10:45 Invited Lecture : Belgian Cancer Registry guidelines for coding and classification of colorectal lesions from 2020: Implementation of the WHO 2019 classification of serrated lesions and update of the general classification rules. N. Van Damme (Belgian Cancer Registry, Brussels), P. Demetter (ULB Bordet, Brussels)
■ 11:30 R04 Primary tumor budding and histological growth patterns of liver metastases in colorectal cancer C. Tonneau (1), A. Bohlok (1), S. Vankerckhove (1), V. Lucidi (2), F. Sandras (3), L. Craciun (1), V. Donckier (1), P. Vermeulen (4), P. Demetter (1) / [1] ULB Bordet, Brussels, [2] C.U.B. ULB Erasme, Brussels, [3] ULB Erasme, Brussels, [4] Sint Augustinus Ziekenhuis GZA, Antwerpen
■ 11:45 R05 An unusual hepatic vascular tumor in a 3-year old child. M. Ahmed, V. Siozopoulou, T. Chapelle, K. Norga, A. Driessen / UZ Antwerpen
■ 12:00 BREAK
Working Group of Digestive Pathology ROOM: ANTWERP
PAVILLON 1F
RID
AY
0
5/
03
| 19 |
13:00-15:30 - SESSION 2
Moderators : A. Driessen (UZ Antwerpen), L. Verset (ULB Bordet, Brussels)
■ 13:00 R06 Grayish macule found in the middle and the lower parts of the esophageal mucosae : a fortuitous discovery. A. Dubail (1), A. Jouret-Mourin (2), P. Collins (3), N. De Suray (4), H. Dano (5) / [1] UCL, Brussels, [2] IPG, Charleroi, [3] Laboratoire CARAD – CHU LIEGE, Laeken (Brussels), [4] Grand Hopital de Charleroi, [5] UCL Saint-Luc, Brussels
■ 13:15 R07 Intratumoral and peritumoral expression of CCR2 in pancreatic adenocarcinoma and its impact on prognosis. C. Bouchart (1), L. Verset (1), P. Demetter (1), A. Boisson (1), M. Hein (2), D. Van Gestel (1), K. Willard-Gallo (1), L. Moretti (1), J. Van Laethem (2) / [1] ULB Bordet, Brussels, [2] ULB Erasme, Bruxelles
■ 13:30 R08 Clinical course and histopathological findings in DGAT1 mutation linked congenital diarrhea. Case report of a 17-year-old patient. E. Deolet, B. Callewaert, J. Geldof, S. Van Biervliet, S. Vande Velde, J. Van Dorpe, M. Van Winckel, A. Hoorens / UZ Gent
■ 13:45 Invited Lecture : Detection and significance of micro-metastases and isolated tumour cells in colorectal cancer lymph nodes. A. Hoorens (UZ Gent)
■ 14:15 R10 Acinar cystic transformation of the pancreas: a case report. M. Ahmed (1), P. De Paepe (1), T. Feryn (1), B. Smet (2), F. Marolleau (2) / [1] AZ Sint-Jan Brugge-Oostende, [2] AZ Delta, Roeselare
■ 14:30 R09 Histological growth patterns of non-colorectal non-breast non-neuroendocrine liver metastases. A. Labar (1), A. Bohlok (1), S. Vankerckhove (1), V. Lucidi (2), P. Demetter (1), P. Vermeulen (3), V. Donckier (1) / [1] ULB Bordet, Brussels, [2] ULB Erasme, [3] Sint Augustinus Ziekenhuis GZA, Antwerpen
■ 14:45 R11 Diagnosis of metastatic cancer in an uncommon location: Importance of clinical-pathological correlation. A. Dubail (1), P. Baldin (2), I. Borbath (2), O. Barbier (2), C. Galant (2) / [1] UCL, Brussels, [2] UCL Saint-Luc, Brussels
■ 15:00 R12 Curious condylomatous lesions of the anal area in a young male patient: not all condylomatous-like lesions are related to HPV infection! J. Schoelinck (1), P. Druez (2), D. Lepore (2), Jl. Dargent (1), A. Jouret-Mourin (1) / [1] Institute of Pathology and Genetics (IPG), Gosselies, [2] GHDC, Charleroi
■ 15:15 R13 Difficulties and pitfalls in the differential diagnosis of IBD: a case report. S. De Froidmont (1)(2), M. Herin (1), B. Calicis (3), P. Warzee (3), G. Beniuga (1), A. Jouret-Mourin (1) / [1] Institut de Pathologie et de Génétique, Gosselies, [2] CHU Liège, [3] Grand Hôpital de Charleroi
■ 15:30 Award Ceremony
ROOM: ANTWERP
PAVILLON 1Working Group of Digestive Pathology
FR
ID
AY
0
5/
03
| 20 |
13:00-14:00 - SESSION 1: Viral hepatitis
Moderators : Ö. Koc (ZOL), J.-P. Mulkay (ULB Saint-Pierre)
■ 13:00 State of the Art : Tips & tricks for the treatment of hepatitis B. T. Vanwolleghem (UZ Antwerpen)
■ 13:30 State of the Art : Tips & tricks for the treatment of hepatitis E. R. A. De Man (Rotterdam, The Netherlands)
■ 14:00 BREAK
14:10-15:10 - SESSION 2 : Clinical cases
Moderators : L. Maccioni (UCL Saint-Luc), J. Verbeek (UZ Leuven)
■ 14:10 C11 Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue with an underlying chronic hepatitis B virus infection: How about aiming at the virus? G. Rasschaert, F. Massaro, T. Sersté, M. Hodoul, M. Vouche, P. Eisendrath, J. Mulkay / CHU Saint-Pierre, Brussels
■ 14:20 C12 Mildly elevated liver enzymes and steatosis: not always NAFLD. T. De Somer (1), W. Kwanten (2), L. Vonghia (2), T. Vanwolleghem (2), T. Steinhauser (2), A. Driessen (2), J. De Winter (2), J. Baets (2), S. Francque (2) / [1] Maria Middelares Ziekenhuis, Gent, [2] UZ Antwerpen
■ 14:30 C13 Recurrent hepatic encephalopathy: beyond infection and GI bleeding. I. Delaleeuwe, N. Vlassenroot, P. Buydens, S. François, H. Reynaert, S. Kindt / UZ Brussel
■ 14:40 C14 Haematochezia in a patient with liver cirrhosis, a portal hypertensive bleed? J. Meesters (1), K. Gysen (2), W. Kwanten (2), T. Vanwolleghem (2), L. Vonghia (2), A. Steinhauser (2), A. Driessen (2), J. Schouten (3), W. Verlinden (3), S. Francque (2) / [1] U Antwerpen [2] UZ Antwerpen, [3] AZ Nikolaas, Sint-Niklaas
■ 14:50 C15 Cessation of Nucleos(t)ide Analogues in long-term virally suppressed chronic hepatitis B patients – close monitoring is key. S. Van Hees (1), G. Dahlqvist (2), B. Delire (2), L. Coubeau (2), J. Henrion (3), T. Vanwolleghem (1) / [1] UZ Antwerpen, [2] UCL Saint-Luc, Brussels, [3] Centres Hospitaliers Jolimont
■ 15:00 C16 Oxaliplatin induced focal nodular hyperplasia of the liver. A. Van Oosterwyck (1), M. Cool (1), G. Lambrecht (1), M. D’hondt (2), G. Vanneste (2), L. Libbrecht (2), G. Deboever (1) / [1] AZ Damiaan, Oostende, [2] AZ Groeninge, Kortrijk
■ 15:10 BREAK
15:15-16:30 - SESSION 3 : Rising stars in the liver community
Moderators : L. Smets (KULeuven), I. Mannaerts (UZ Brussel)
■ 15:15 Best MSD clinical paper at BASL winter meeting: Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity. Hannelie Korf (UZ Leuven)
■ 15:40 Best MSD basic paper at BASL winter meeting: Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine non-alcoholic fatty liver disease. Sander Lefere (UGent)
■ 16:05 Young Investigator’s presentation: NAFLD in type 1 diabetes: should we extend our view? Jonathan Mertens (UAntwerpen)
■ 16:15 Young Investigator’s presentation: Arthur de Schaetzen
■ 16:25 Closing of meeting
Young BASL ROOM: BRUSSELS
PAVILLON 1F
RID
AY
0
5/
03
| 21 |
FR
ID
AY
0
5/
03
BSGIE live endoscopy Symposium ROOM: GENT
Moderators : P. Eisendrath (ULB Saint-Pierre), E. Toussaint (CHU Charleroi), P. Dewint (UZ Gent), A. Lemmers (ULB Erasme)
■ 09:00 Introduction A. Lemmers (ULB Erasme)
■ 09:05-10:30 POEM - Type III Achalasia R. Bisschops (UZ Leuven), V. Huberty (ULB Erasme)
Endoscopic treatment of Zenker’s diverticulum-redo, Septotomy D. Blero (ULB Erasme), M. Aerts (UZ Brussel)
CLINICAL CASE presentations by BygGIE (Belgian young group of GI Endoscopists):
■ G21 Michiel Bronswijk (Imeldaziekenhuis Bonheiden)
10:30-10:45 CASE REPORTS will be presented as illustration of the live cases:
■ G18 Minimally Invasive Treatment of a Bulging Appendiceal Orifice: A Case Report. F. Lansink (1), C. Jorissen (1), P. Cuyle (2), M. Bronswijk (2) / [1] KU Leuven, [2] Imelda Hospital, Bonheiden
■ G19 Where does all the air come from? M. Surmont, M. Schils, S. Kindt / UZ Brussel
■ G20 Working under pressure – insufflation-induced gastric barotrauma during esophageal ESD. D. Persyn, D. De Wulf, R. Bisschops / UZ Leuven
■ 10:45-11:15 Video-slides Manometry H. Louis (ULB Erasme)
■ 11:15-12:00 Type I Achalasia – Pneumatic dilation 30mm M. Aerts (UZ Brussel), H. Louis (ULB Erasme)
Peg-J/PeJ (discussion G-POEM) M. Arvanitakis (ULB Erasme), Y. Mourabit (CHU Charleroi)
CLINICAL CASE presentations by BygGIE (Belgian young group of GI Endoscopists):
■ G22 Stefan Van Langendonck (AZ Maria Middelares, Gent)
■ G23 Gertjan Rasschaert (UZ Brussel, Brussel)
PAVILLON 2F
RID
AY
0
5/
03
| 22 |
FR
ID
AY
0
5/
03
Best of BWGE 2021! ROOM: GENT
14:00-15:00
Moderators : S. Francque (UZ Antwerpen), I. Colle (ASZ Aalst/UG)
■ GE01 The DOMINO study: Diet Or Medication in primary care patients with Irritable bowel syndrome. F. Carbone (1), K. Van Den Houte (1), L. Besard (2), C. Tack (1), S. Ceulemans (2), J. Biesiekierski (3), C. Matthys (2), J. Arts (4), P. Caenepeel (5), H. Piessevaux (6), A. Vandenberghe (2), M. Jones (7), J. Tack (2) / [1] KULeuven, [2] UZ Leuven, [3] La Trobe University, Victoria, Australia, [4] AZ Sint-Lucas Brugge, [5] Ziekenhuis Oost Limbug (ZOL), Genk, [6] UCL Saint-Luc, Brussels, [7] Macquarie University, Australia
Other best presentations selected by the different session chairs will be included in the session.
We thank you for attending BWGE 2021 in a digital format!
PAVILLON 2F
RID
AY
0
5/
03
| 23 |
09:00-09:50 - SESSION 1
Moderators : S. Carton (AZ Imelda, Bonheiden), E. Van Cutsem (UZ Leuven)
■ 09:00 O01 Across the cross: primary surgery not inferior to neoadjuvant chemoradiotherapy followed by surgery for locally advanced oesophageal adenocarcinoma. A.bouckaert, J. Moons, W. Coosemans, L. Depypere, P. Nafteux / UZ Leuven
■ 09:10 O02 Presumed metastatic, but worthwhile to operate: not all clinically positive cervical lymph nodes imply the same prognosis in oesophageal adenocarcinoma – the correct assumption within TNM 8th for oesophageal cancers. S. Vanstraelen, J. Moons, H. Van Veer, W. Coosemans, P. Nafteux (1), L. Depypere (1) / UZ Leuven
■ 09:20 O03 Response prediction of rectal cancer to chemoradiotherapy: a random subspace decision forest analysis. A. Sermeus, C. Raets, C. El Aisati, B. Engels, T. Gevaert, M. De Ridder, K. Barbé / UZ Brussel
■ 09:30 -09:50 Discussion + Q&A K. Geboes / UZ Gent/UGent
■ 09:50 Flash Ipsen
10:00-10:50 - SESSION 2
■ 10:00 O04 Sequential changes of histological growth patterns of colorectal liver metastases during disease progression. N. El Nakadi (1), A. Bohlok (1), S. Vankerckhove (1), V. Lucidi (2), A. Hendlisz (1), J. Van Laethem (2), P. Demetter (1), V. Donckier (1), P. Vermeulen (6) / [1] ULB Bordet, Brussels, [2] C.U.B. ULB Erasme, Brussels, [3] Sint Augustinus Ziekenhuis GZA, Antwerpen
■ 10:10 O05 The histological growth pattern and the clinico-metabolic characteristics accurately predict the outcome in patients undergoing surgery for colorectal liver metastases. A. Bohlok (1), H. Azema (1), I. Duran Derijckere (1), S. Vankerckhove (1), V. Lucidi (3), J. Van Laethem (2), A. Hendlisz (1), S. Goldman (2), P. Flamen (1), L. Craciun (1), F. Sandras (2), P. Demetter (1), P. Vermeulen (9), V. Donckier (1) / [1] ULB Bordet, Brussels, [2] ULB Erasme, Brussels, [3] Sint Augustinus Ziekenhuis GZA, Antwerpen
■ 10:20 O06 Prognostic value of baseline and early changes of circulating cell-free (cf) DNA in the neoadjuvant setting of early stage colon cancer. G. Bregni (1), E. Trevisi (1), C. Senti (1), A. Pretta (1), C. Vandeputte (1), P. Kehagias (1), E. Acedo Reina (1), A. Deleporte (1), P. Gkolfakis (1), J. Van Laethem (2), P. Vergauwe (3), M. Van Den Eynde (4), G. Deboever (5), J. Janssens (6), G. Demolin (7), S. Holbrechts (8), M. Clausse (9), T. De Grez (10), M. Peeters (11), L. D’hondt (12), K. Geboes (13), T. Besse-Hammer (14), A. Buggenhout (12), F. Rothé (1), P. Flamen (1), A. Hendlisz (1), F. Sclafani (1) / [1] ULB Bordet, Brussels, [2] ULB Erasme, Brussels, [3] AZ Groeninge, Kortrijk, [4] UCL Saint-Luc, Brussels, [5] AZ Damiaan, Oostende, [6] AZ Turnhout, [7] CHC St-Joseph, Liège, [8] CHU Ambroise Paré Mons, [9] UCL Saint-Luc Bouge, Namur, [10] CHR, Namur, [11] UZ Antwerpen, [12] CHU UCL Namur, Site de Godinne, Yvoir, [13] UZ Gent, [14] CHU Brugmann, Brussels
■ 10:30-10:50 Discussion + Q&A P. Pauwels / UZA/UA
BGDO ROOM: LIEGE
FR
ID
AY
0
5/
03
PAVILLON 2
■ 08:00 - 09:00 Satellite Symposium MSD: Evolving landscape of metastatic colorectal cancer management. Speakers: M. Peeters, UZ Antwerpen / E. Van Cutsem, UZ Leuven /
M. Van den Eynde, UCL Saint-Luc / P. Pauwels, UZ Antwerpen
| 24 |
11:20-12:10 - SESSION 3
Moderators : L. Mortier (AZ St Maarten, Mechelen), J. Carrasco (Grand Hôpital Charleroi)
■ 11:20 O07 Interim analysis of the AVETUXIRI trial: avelumab with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) – A proof of concept, open label, non-randomized phase IIA study. N. Huyghe (1), I. Sinapi (2), A. De Cuyper (1), M. Ferrier (1), M. Gilet (2), P. Goffette (1), B. Ghaye (1), A. Van Maanen (1), M. Castella (1), J. Galon (3), J. Carrasco (2), M. Vandeneynde (1) / [1] UCL Saint-Luc, Brussels, [2] Grand Hopital de Charleroi, [3] Centre de Recherche des Cordeliers, Paris, France
■ 11:30 O08 Randomized Phase 2 study comparing pathological responses of resected colorectal cancer metastases (CRCM) after bevacizumab (BEV) with FOLFOX or FOLFIRI (BEV-ONCO trial). P. Baldin (1), G. Beniuga (2), A. Jouret-Mourin (1), G. Demolin (3), S. Roland (4), L. D’hondt (5), P. Vergauwe (6), D. Van Daele (7), M. Mailleux (8), I. Sinapi (9), A. De Cuyper (1), N. Bletard (3), B. Massart (3), M. Delos (5), M. Castella (1), A. Van Maanen (1), J. Carrasco (9), M. Vandeneynde (1) / [1] UCL Saint-Luc, Brussels, [2] IPG, Charleroi, [3] Clinique du Mont Légia, Liège, [4] CHIREC, Brussels, [5] CHU Mont-Godinne, [6] AZ Groeninge, Kortrijk, [7] CHU de Liège, [8] UCL Saint-Luc Bouge, Namur, [9] Grand Hopital de Charleroi
■ 11:40 O09 Sex and regorafenib toxicity in refractory colorectal cancer: a safety analysis of the RegARd-C trial. C. Vandeputte (1), G. Bregni (1), P. Gkolfakis (1), T. Guiot (1), P. Kehagias (1), A. Pretta (1), C. Senti (1), E. Acedo Reina (1), N. Kindt (1), A. Deleporte (1), K. Geboes (2), T. Delaunoit (3), G. Demoulin (4), M. Peeters (5), L. D’hondt (6), J. Janssens (7), J. Carrasco (8), S. Holbrechts (9), J. Goeminne (10), P. Vergauwe (11), J. Van Laethem (12), P. Flamen (1), P. Demetter (13), A. Hendlisz (1), F. Sclafani (1) / [1] ULB Bordet, Brussels, [2] UZ Gent, [3] Hopital de Jolimont, La Louvière, [4] CHC, Liège, [5] UZ Antwerpen, [6] CHU UCL Namur, Yvoir, [7] AZ Turnhout, [8] Grand Hopital de Charleroi, [9] CHU Ambroise Paré, Mons, [10] Cliniques et Maternité Ste Elisabeth Namur, [11] AZ Groeninge, Kortrijk, [12] Erasme Hospital, Brussels, [13] ULB Bordet
■ 11:40 -12:00 Discussion + Q&A Jeroen Dekervel / UZ Leuven
■ 12:10 Flash EISAI/MSD Speaker : Dr Demolin / Clinique du Mont Légia, Liège
12:10-12:55 - SESSION 4
■ 12:20 O10 Tumor-Associated Copy Number Alterations in Plasma Cell-Free DNA from Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm patients. G. Boons (1), T. Vandamme (1), W. Lybaert (2), G. Roeyen (1), T. Rondou (3), K. Papadimitriou (1), K. Janssens (1), W. Demey (4), I. Dero (5), G. Van Camp (1), M. Peeters (1), K. Op De Beeck (1) / [1] U Antwerp/UZ Antwerpen,[2] AZ Nikolaas, Sint-Niklaas, [3] AZ Rivierenland Bornem, [4] AZ Klina,Brasschaat, [5] Sint Augustinus Ziekenhuis GZA, Antwerpen
■ 12:30 O11 First clinical experience with Atezolizumab/Bevacizumab in advanced hepatocellular carcinoma. S. Cappuyns, V. Vandecaveye, T. Roskams, E. Van Cutsem, C. Verslype, J. Dekervel / UZ Leuven
■ 12:40 -12:50 Discussion + Q&A Ivan Borbath / UCL
■ 12:50 -12:55 BGDO Award and adjournment, M. Peeters / chair BGDO, UZA
BGDO ROOM: LIEGE
FR
ID
AY
0
5/
03
PAVILLON 2
■ 10:50 - 11:20 Satellite Symposium SERVIER: Current & future management of advanced gastric cancer Speaker: E. SMYTH,
Cambridge University Hospitals NHS Foundation Trust, UK
| 25 |
ROOM: LIEGE
PAVILLON 2
INTRODUCTION PIERRE DEPREZ
Moderators : I. Scheers (UCL, Brussels), G. Roeyen (UZ Antwerpen)
■ 14:00 P01 Splenic vascular patency after spleen and vessel preserving distal pancreatectomy: Is the Kimura technique worth the effort? L. Abreu De Carvalho (1), S. Castro (1), O. Uyttebroek (2), A. Vanlander (1), S. Ribeiro (2), A. Hoorens (2), F. Berrevoet (1) / [1] UZ Gent, [2] KU Leuven
■ 14:15 P02 Total pancreatectomy with islet auto transplantation – a new treatment option For chronic pancreatitis patients in Belgium. H. Van Malenstein (1), D. De Paep (2), Z. Ling (2), H. Verbeke (1), G. Maleux (1), Y. Debaveye (1), S. Van Der Merwe (1), D.jacobs-Tulleneers-Thevissen (2), J. Pirenne (1), P. Gillard (1) / [1] UZ Leuven, [2] UZ Brussel, VUB
■ 14:30 P03 Prevalence of non-alcoholic fatty liver disease after extensive pancreatic surgery in a Belgian cohort. A. De Zutter, M. Van Den Broecke, S. Ribeiro, P. Smeets, L. Abreu De Carvalho, F. Berrevoet, K. Geboes / UZ Gent
■ 14:45 P04 Pancreatic blunt trauma in children: report from the Belgian Pancreatic Trauma Group. I. Scheers (1), G. Roeyen (2), F. Berrevoet (3), I. Hoffman (4), A. Lhomme (5), O. Bauraind (6), M. Delhaye (7), P. Deprez (1) / [1] UCL Saint-Luc, Brussels, [2] UZ Antwerpen, [3] UZ Gent, [4] UZ Leuven, [5] CHR La Citadelle, Liège, [6] Hopital CHC, Liège, [7] ULB Erasme, Brussels
■ 15:00 P05 Icterus caused by annular pancreas and associated intraluminal duodenal diverticulum. J. Vandewalle (1), F. Gelders (1), M. Struyve (2) / [1] KU Leuven, [2] Ziekenhuis Oost Limbug (ZOL), Genk.
■ 15:15 P06 Differential diagnosis for multiple pancreatic cystic lesions. R. Garcés-Duran (1), L. Monino (1), V. Nguenang (2), P. Deprez (1) / [1] UCL Saint-Luc, Brussels, [2] CHR Namur
Moderator : M. Arvanitakis (ULB Erasme, Brussels)
■ 15:30 Invited Lecture: When and how to operate in patients with chronic pancreatitis Prof. Dr. M.G. Besselink (AMC UMC The Netherlands)
Belgian Pancreatic Club
FR
ID
AY
0
5/
03
ePOSTERS
BASLePOSTERS PAVILLON
■ A20 Lower abundance of Clostridium sensu stricto is associated with liver steatosis and fibrosis severity in a prospective cohort of obese patients with metabolic dysfunction-associated fatty liver disease. N. Lanthier, J. Rodriguez, M. Nachit, S. Hiel, P. Trefois, A. Neyrinck, P. Cani, L. Bindels, J. Thissen, N. Delzenne / UCL Saint-Luc, Brussels
■ A21 Endothelin receptor antagonist bosentan improves microvascular structural disruption in a rat model of early NAFLD. D. Van Der Graaff (1), W. Kwanten (2), C. Casteleyn (3), B. De Winter (1), J. De Man (1), L. Vonghia (2), S. Francque (2) / [1] U Antwerpen, [2] UZA Antwerpen, [3] U Gent
■ A22 The prevalence of disorders of the gut brain axis in type 2 diabetes mellitus with non-alcoholic fatty liver disease: preliminary results from an observational study. T. Van Nieuwenhove, G. Rasschaert, S. Kindt, A. Kharagijtsing / UZ Brussel
■ A23 Local control of hepatocellular carcinoma and colorectal liver metastases after microwave ablation only without concomitant hepatectomy. L. Abreu De Carvalho, S. Van Cleven, A. Vanlander, F. Berrevoet/ U Gent
■ A24 Retrospective Audit of the Quality of Intraoperative Cholangiogram during Laparoscopic Cholecystectomy. R. Huynh, M. Magdy, S. Badiani / University New South Wales, Sydney, Australia
■ A25 The role of estimated glucose disposal rate (eGDR) as a predictor of insulin resistance, NAFLD and cardiovascular complications. J. Mertens, J. Weyler, E. Dirinck, L. Vonghia, L. Mortelmans, C. De Block, S. Francque / UZ Antwerpen
■ A26 Ascitic fluid infection in patients with chronic liver disease: A single center study. H. Kamal, S. Kamal, S. Abdelhakam, Y. Massoud, K. Abd El Aziz / University Ain Shams, Egypt
■ A27 Increased prevalence of hepatitis C in patients admitted in psychiatric centres. H. Ruymbeke (1), J. Schouten (2), C. Van Steenkiste (3), S. Bourgeois (4), W. Verlinden (2) / [1] U Gent, [2] AZ Nikolaas, Sint-Niklaas, [3] AZ Maria Middelares, Gent, [4] ZNA Antwerpen
D I G I TA L
ePOSTERS
IBD - BIRDePOSTERS PAVILLON
■ I16 Real world effectiveness of ustekinumab and tofacitinib in ulcerative colitis. M. Truyens, J. Geldof, G. Dewitte, A. Peeters, E. Glorieus, T. Lobaton Ortega / UZ Gent
■ I17 Effects of concomitant steroids on a prognostic blood gene expression biomarker for inflammatory bowel disease. D. Alsoud (1), S. Verstockt (1), J. Sabino (1), M. Ferrante (1), N. Noor (2), B. Verstockt (1), S. Vermeire (1) / [1] KU Leuven, [2] Addenbrooke’s Hospital Cambridge University, United Kingdom
■ I18 Single-cell RNA sequencing to unravel the cellular heterogeneity, inter- cellular communication and spatial organization in human intestinal tissue remodelling in Crohn’s disease. B. Ke (2), S. Abdu Rahiman (2), G. Dragoni (2), B. Verstockt (1), G. De Hertogh (2), S. Vermeire (1), G. Matteoli (2) / [1] UZ Leuven, [2] KU Leuven
D I G I TA L
FR
ID
AY
0
5/
03
FR
ID
AY
0
5/
03
ePOSTERS
BeSPGHANePOSTERS PAVILLON
■ K06 How to manage constipation: a Belgian national survey. R. Lemmens, K. Huysentruyt, B. Hauser, E. Degreef, G. Veereman, T. Devreker, Y. Vandenplas / UZ Brussel
■ K07 Safety and tolerance of a novel anti-regurgitation formula combining carob bean gum, prebiotics and partly fermented formula with postbiotics: a double-blind, randomized, controlled trial. Y. Vandenplas (1), M. Bellaiche (2) / [1] UZ Brussel [2] Hôpital Robert Debré, Paris, France
■ K08 Expanding the phenotypic spectrum of mutations in DCDC2 with central nervous system impairment. H. Syryn, B. Callewaert, A. Hoorens, S. Vande Velde, M. Van Winckel, S. Van Biervliet, P. Verloo, R. De Bruyne / U Gent
■ K09 Postponed analysis of lactose hydrogen breath test samples. M. Willsemsen, V. Kris, Y. Vandenplas / UZ Brussel
D I G I TA L
BWGE Event Coordination : DME Events • Anne-France De Meyer • 57 av. G Demey 1160 Bruxelles • [email protected] • Tel : 0477 27 00 45
WITH THE KIND SUPPORT OF
BAYER • BMS • COOK MEDICAL • EISAI / MSD • GALAPAGOS • IPSEN • NORGINE • OLYMPUS • ONIS •
PFIZER • ROCHE • SANDOZ
ABBVIE • ACTA GASTROENTEROLOGICA • AMGEN • BIOCODEX • BOUCART MEDICAL • CSL BEHRING • DR FALK PHARMA • ERBE • GBS-VBS •
INCYTE • MAYOLY • REVOGAN • SIRTEX • TRUVION HEALTHCARE
FAPA
P L A T I N U M
G O L D
S I L V E R
B R O N Z E
A s s o c i a t i o n
XXXIIIrd Edition – 03 > 05.03.21 – A DIGITAL EXPERIENCE
